Peptides for Sexual Wellness

Sexual wellness peptides represent a significant shift from the traditional approach to sexual dysfunction. Since the introduction of Viagra in 1998, the dominant paradigm has been PDE5 inhibition, which works by increasing blood flow to erectile tissue. This mechanism addresses the hydraulic component of sexual function but does nothing for desire, arousal initiation, or the brain's sexual processing networks. Sexual wellness peptides work upstream, in the brain, where sexual desire and arousal originate. PT-141 (bremelanotide) is the most established sexual wellness peptide. It received FDA approval as Vyleesi in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first FDA-approved treatment that works through central melanocortin pathways rather than peripheral blood flow. It activates MC4R receptors in the hypothalamus, and Phase 3 trials showed statistically significant improvements in sexual desire scores and reductions in associated distress. In men, PT-141 has been studied for erectile dysfunction and shown to produce erections through a mechanism independent of nitric oxide/PDE5, making it potentially useful for men who don't respond to Viagra or Cialis. Oxytocin's role in sexual function is well-established physiologically but harder to capture therapeutically. Oxytocin levels rise during sexual arousal and peak at orgasm. Intranasal oxytocin has been studied for enhancing sexual experience, with some positive findings (improved arousal, stronger orgasm, enhanced emotional connection) but inconsistent replication. The challenge may be delivery: how much intranasal oxytocin actually reaches central receptors is still debated. Kisspeptin is newer to the sexual wellness space. Comninos et al. published data showing that IV kisspeptin enhanced brain processing of sexual stimuli (measured by fMRI) and increased penile tumescence in healthy men. It works by stimulating GnRH neurons, which drive LH and FSH release and may also have direct effects on sexual processing centers in the brain. The hormonal foundation shouldn't be overlooked. Testosterone, estradiol, and DHEA are not peptides, but optimizing these hormones is often the first step in addressing sexual dysfunction. Low testosterone is the most common hormonal cause of low libido in men, and declining estradiol contributes to sexual dysfunction in postmenopausal women. Costs range from $50-300/month. PT-141 through compounding pharmacies is the most common choice for direct sexual function support. Oxytocin is affordable at $40-100/month. Hormonal optimization (TRT, estradiol) costs vary based on the specific protocol.